Kenneth L Rice

US Patent:

6436923, Aug 20, 2002

Filed:

Mar 17, 2000

Appl. No.:

09/527750

Inventors:

Shripad S. Bhagwat - San Diego CA
Bernd M. Stein - San Diego CA
Qi Chao - San Diego CA
Anthony R. Gangloff - Pacifica CA
Jeffrey A. McKie - San Diego CA
Kenneth D. Rice - Mill Valley CA

Assignee:

Signal Pharmaceuticals, Inc. - San Diego CA

International Classification:

C07D21718

US Classification:

51421301, 546144, 546140, 540593, 540597, 514307, 51421704, 5142352, 5142282, 514308, 51425305, 544128, 544 62, 544363

Abstract:

Compounds that modulate the estrogen receptor (ER) are disclosed, as well as pharmaceutical compositions containing the same. In a specific embodiment, the compounds are selective modulators for ER- over ER-. Methods are disclosed for modulating ER- in cell and/or tissues expressing the same, including cells and/or tissue that preferentially express ER-. More generally, methods for treating estrogen-related conditions are also disclosed, including conditions such as is breast cancer, testicular cancer, osteoporosis, endometriosis, cardiovascular disease, hypercholesterolemia, prostatic hypertrophy, prostatic carcinomas, obesity, hot flashes, skin effects, mood swings, memory loss, urinary incontinence, hairloss, cataracts, natural hormonal imbalances, and adverse reproductive effects associated with exposure to environmental chemicals.

US Patent:

6593322, Jul 15, 2003

Filed:

Sep 21, 2000

Appl. No.:

09/668893

Inventors:

Shripad S. Bhagwat - San Diego CA
Bernd M. Stein - San Diego CA
Qi Chao - San Diego CA
Anthony R. Gangloff - Daly City CA
Jeffrey A. McKie - San Diego CA
Kenneth D. Rice - Mill Valley CA

Assignee:

Signal Pharmaceuticals, Inc. - San Diego CA

International Classification:

C07D21718

US Classification:

51421301, 546144, 546140, 540539, 540597, 514307, 51421704, 5142352, 5142282, 514308, 51425305, 544128, 544 62, 544363

Abstract:

Compounds that modulate the estrogen receptor (ER) are disclosed, as well as pharmaceutical compositions containing the same. In a specific embodiment, the compounds are selective for ER- over ER-. Methods are disclosed for modulating ER- in cell and/or tissues expressing the same, including cells and/or tissue that preferentially ER-. Methods for treating estrogen-related conditions are also disclosed, including conditions such as is breast cancer, testicular cancer, osteoporosis, endometriosis, cardiovascular disease, hypercholesterolemia, prostatic hypertrophy, prostatic carcinomas, obesity, hot flashes, skin effects, mood swings, memory loss, urinary incontinence, hairloss, cataracts, natureal hormonal imbalances, and adverse reproductive effects associated with exposure to environmental chemicals.

US Patent:

7279489, Oct 9, 2007

Filed:

May 7, 2003

Appl. No.:

10/434341

Inventors:

Shripad S. Bhagwat - San Diego CA, US
Bernd M. Stein - San Diego CA, US
Qi Chao - San Diego CA, US
Anthony R. Gangloff - Daly City CA, US
Jeffrey A. McKie - San Diego CA, US
Kenneth D. Rice - Mill Valley CA, US

Assignee:

Signal Pharmaceuticals, LLC - San Diego CA

International Classification:

A61P 35/00
A61K 31/47
C07D 217/00

US Classification:

514307, 546144

Abstract:

Compounds that modulate the estrogen receptor (ER) are disclosed, as well as pharmaceutical compositions containing the same. In a specific embodiment, the compounds are selective for ER-β over ER-α. Methods are disclosed for modulating ER-β in cell and/or tissues expressing the same, including cells and/or tissue that preferentially ER-β. Methods for treating estrogen-related conditions are also disclosed, including conditions such as is breast cancer, testicular cancer, osteoporosis, endometriosis, cardiovascular disease, hypercholesterolemia, prostatic hypertrophy, prostatic carcinomas, obesity, hot flashes, skin effects, mood swings, memory loss, urinary incontinence, hairloss, cataracts, natureal hormonal imbalances, and adverse reproductive effects associated with exposure to environmental chemicals.